Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NOURA J CHOUDHURY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1841649332
CMS profile
1454063
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$8,282.71

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $7,225.00 1
Travel and Lodging $930.71 5
Food and Beverage $127.00 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $8,282.71 9

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NOURA J CHOUDHURY

NPI 1841649332 · CMS profile ID 1454063

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841649332?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NOURA J CHOUDHURY, NPI 1841649332, CMS profile ID 1454063. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841649332?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). NOURA J CHOUDHURY, NPI 1841649332, CMS profile ID 1454063. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841649332?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
NOURA J CHOUDHURY, NPI 1841649332, CMS profile ID 1454063, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1841649332?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $8,282.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $35.0001/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049645695 CMS
GENZYME CORPORATION $115.4101/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049645701 CMS
GENZYME CORPORATION $127.2101/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049645707 CMS
GENZYME CORPORATION $422.3501/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049645711 CMS
GENZYME CORPORATION $7,225.0001/27/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049646101 CMS
GENZYME CORPORATION $230.7401/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049646107 CMS
GENZYME CORPORATION $20.0001/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049646113 CMS
GENZYME CORPORATION $36.0001/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049646121 CMS
GENZYME CORPORATION $71.0001/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049646127 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $194.00 2
PY2022 $15.50 1
PY2023 $8,282.71 9
PY2024 $14,757.57 11
PY2025 $15,377.47 14

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,427.64 2
PY2025 Principal investigator $307,356.67 66
PY2024 Principal investigator $1,388,670.65 463
PY2023 Principal investigator $1,562,080.65 113
PY2022 Principal investigator $223,487.22 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

113 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,003.00 12/31/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors. No dispute reported 06/30/2026 998413431
Principal investigator 1 Merck Sharp & Dohme LLC $16,353.74 12/31/2023 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer KEYNOTE-B99 No dispute reported 06/30/2026 1042520435
Principal investigator 1 Merck Sharp & Dohme LLC $129,898.75 12/31/2023 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer KEYNOTE-B99 No dispute reported 06/30/2026 1042520585
Principal investigator 1 Merck Sharp & Dohme LLC $89,214.18 12/31/2023 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib MK-7339, Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Na Limited-Stage Small Cell Lung Cancer LS-SCLC No dispute reported 06/30/2026 1042543479
Principal investigator 1 Merck Sharp & Dohme LLC $163,826.36 12/31/2023 Non-covered Recipient Entity
Memorial Sloan Kettering - Basking Ridge
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib MK-7339, Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Na Limited-Stage Small Cell Lung Cancer LS-SCLC No dispute reported 06/30/2026 1042545301
Principal investigator 1 Merck Sharp & Dohme LLC $89,420.46 12/31/2023 Non-covered Recipient Entity
Memorial Sloan Kettering - Westchester-Thoracic Oncology
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib MK-7339, Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Na Limited-Stage Small Cell Lung Cancer LS-SCLC No dispute reported 06/30/2026 1042545321
Principal investigator 1 Merck Sharp & Dohme LLC $74,977.98 12/31/2023 Non-covered Recipient Entity
Memorial Sloan Kettering - Monmouth
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib MK-7339, Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Na Limited-Stage Small Cell Lung Cancer LS-SCLC No dispute reported 06/30/2026 1042545343
Principal investigator 1 Merck Sharp & Dohme LLC $292,380.12 12/31/2023 Non-covered Recipient Entity
Memorial Sloan Kettering - Bergen
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib MK-7339, Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Na Limited-Stage Small Cell Lung Cancer LS-SCLC No dispute reported 06/30/2026 1042546941
Principal investigator 1 Merck Sharp & Dohme LLC $88,956.54 12/31/2023 Non-covered Recipient Entity
Memorial Sloan Kettering - Nassau
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib MK-7339, Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Na Limited-Stage Small Cell Lung Cancer LS-SCLC No dispute reported 06/30/2026 1042547709
Principal investigator 1 Merck Sharp & Dohme LLC $181,317.40 12/31/2023 Non-covered Recipient Entity
Memorial Sloan Kettering- Commack
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib MK-7339, Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Na Limited-Stage Small Cell Lung Cancer LS-SCLC No dispute reported 06/30/2026 1042547725
Principal investigator 1 ABBVIE INC. $2,930.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412497
Principal investigator 1 ABBVIE INC. $4,244.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412509
Principal investigator 1 ABBVIE INC. $4,244.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412511
Principal investigator 1 ABBVIE INC. $2,643.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412513
Principal investigator 1 ABBVIE INC. $2,643.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412519
Principal investigator 1 ABBVIE INC. $2,643.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412521
Principal investigator 1 ABBVIE INC. $2,643.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412593
Principal investigator 1 ABBVIE INC. $2,643.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412595
Principal investigator 1 ABBVIE INC. $2,930.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412597
Principal investigator 1 ABBVIE INC. $2,930.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412599
Principal investigator 1 ABBVIE INC. $4,432.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412601
Principal investigator 1 ABBVIE INC. $2,643.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412639
Principal investigator 1 ABBVIE INC. $2,643.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412701
Principal investigator 1 ABBVIE INC. $2,643.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412703
Principal investigator 1 ABBVIE INC. $4,432.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412705
Principal investigator 1 ABBVIE INC. $2,643.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412717
Principal investigator 1 ABBVIE INC. $2,643.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412719
Principal investigator 1 ABBVIE INC. $2,930.00 12/21/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412721
Principal investigator 1 ABBVIE INC. $2,643.00 12/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998411773
Principal investigator 1 ABBVIE INC. $3,035.00 12/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998411791
Principal investigator 1 ABBVIE INC. $4,244.00 12/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998411793
Principal investigator 1 ABBVIE INC. $2,971.00 12/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998411813
Principal investigator 1 ABBVIE INC. $4,432.00 12/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998411815
Principal investigator 1 ABBVIE INC. $2,643.00 12/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998411817
Principal investigator 1 ABBVIE INC. $2,930.00 12/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998411863
Principal investigator 1 ABBVIE INC. $2,930.00 12/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998411865
Principal investigator 1 ABBVIE INC. $4,432.00 12/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998411885
Principal investigator 1 ABBVIE INC. $4,244.00 12/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998411887
Principal investigator 1 ABBVIE INC. $2,643.00 12/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998411889
Principal investigator 1 ABBVIE INC. $2,643.00 12/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412213
Principal investigator 1 ABBVIE INC. $2,643.00 12/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412215
Principal investigator 1 ABBVIE INC. $4,432.00 12/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998412225
Principal investigator 1 F. Hoffmann-La Roche AG $6,152.96 12/14/2023 Non-covered Recipient Entity
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC No dispute reported 06/30/2026 1040498867
Principal investigator 1 F. Hoffmann-La Roche AG $1,808.83 12/14/2023 Non-covered Recipient Entity
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC No dispute reported 06/30/2026 1040498883
Principal investigator 1 F. Hoffmann-La Roche AG $8,608.68 12/14/2023 Non-covered Recipient Entity
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC No dispute reported 06/30/2026 1040498899
Principal investigator 1 F. Hoffmann-La Roche AG $2,926.00 12/14/2023 Non-covered Recipient Entity
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC No dispute reported 06/30/2026 1040498915
Principal investigator 1 F. Hoffmann-La Roche AG $8,483.32 12/14/2023 Non-covered Recipient Entity
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC No dispute reported 06/30/2026 1040498929
Principal investigator 1 Merck Sharp & Dohme LLC $73,985.60 12/13/2023 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer KEYNOTE-B99 No dispute reported 06/30/2026 1042520613
Principal investigator 1 ABBVIE INC. $4,244.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408843
Principal investigator 1 ABBVIE INC. $2,930.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408845
Principal investigator 1 ABBVIE INC. $2,930.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408847
Principal investigator 1 ABBVIE INC. $2,994.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408849
Principal investigator 1 ABBVIE INC. $4,432.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408851
Principal investigator 1 ABBVIE INC. $2,994.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408871
Principal investigator 1 ABBVIE INC. $2,930.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408873
Principal investigator 1 ABBVIE INC. $2,930.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408875
Principal investigator 1 ABBVIE INC. $3,035.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408877
Principal investigator 1 ABBVIE INC. $2,930.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408879
Principal investigator 1 ABBVIE INC. $2,994.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408901
Principal investigator 1 ABBVIE INC. $2,930.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408903
Principal investigator 1 ABBVIE INC. $2,930.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408905
Principal investigator 1 ABBVIE INC. $2,643.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408911
Principal investigator 1 ABBVIE INC. $2,643.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408913
Principal investigator 1 ABBVIE INC. $2,643.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408919
Principal investigator 1 ABBVIE INC. $2,994.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408921
Principal investigator 1 ABBVIE INC. $4,244.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408923
Principal investigator 1 ABBVIE INC. $3,035.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408929
Principal investigator 1 ABBVIE INC. $2,971.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408931
Principal investigator 1 ABBVIE INC. $2,994.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408933
Principal investigator 1 ABBVIE INC. $2,971.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408935
Principal investigator 1 ABBVIE INC. $4,244.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408937
Principal investigator 1 ABBVIE INC. $4,244.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408959
Principal investigator 1 ABBVIE INC. $2,643.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408961
Principal investigator 1 ABBVIE INC. $2,930.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408963
Principal investigator 1 ABBVIE INC. $2,994.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408965
Principal investigator 1 ABBVIE INC. $2,643.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408967
Principal investigator 1 ABBVIE INC. $2,930.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408973
Principal investigator 1 ABBVIE INC. $2,930.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408975
Principal investigator 1 ABBVIE INC. $5,351.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408977
Principal investigator 1 ABBVIE INC. $2,643.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408981
Principal investigator 1 ABBVIE INC. $5,351.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408983
Principal investigator 1 ABBVIE INC. $3,035.00 11/28/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998408985
Principal investigator 1 ABBVIE INC. $4,097.00 11/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998407925
Principal investigator 1 ABBVIE INC. $1,756.00 11/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998407927
Principal investigator 1 ABBVIE INC. $2,600.00 11/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998407939
Principal investigator 1 ABBVIE INC. $2,841.00 11/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998407941
Principal investigator 1 ABBVIE INC. $19,618.00 11/14/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998407973
Principal investigator 1 ABBVIE INC. $4,432.00 10/26/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998405365
Principal investigator 1 ABBVIE INC. $2,971.00 10/26/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998405367
Principal investigator 1 ABBVIE INC. $5,351.00 10/26/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998405369
Principal investigator 1 ABBVIE INC. $2,930.00 10/26/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998405371
Principal investigator 1 ABBVIE INC. $3,035.00 10/26/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998405373
Principal investigator 1 ABBVIE INC. $2,930.00 10/26/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998405375
Principal investigator 1 ABBVIE INC. $2,930.00 10/26/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998405377
Principal investigator 1 ABBVIE INC. $4,432.00 10/26/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998405379
Principal investigator 1 ABBVIE INC. $3,035.00 10/26/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998405381
Principal investigator 1 ABBVIE INC. $3,035.00 10/26/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998405383
Principal investigator 1 ABBVIE INC. $2,971.00 10/26/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998405385
Principal investigator 1 ABBVIE INC. $5,351.00 10/26/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998405387
Principal investigator 1 ABBVIE INC. $3,035.00 10/26/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998405389
Principal investigator 1 ABBVIE INC. $3,035.00 10/12/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998404225
Principal investigator 1 ABBVIE INC. $4,432.00 10/12/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998404227
Principal investigator 1 ABBVIE INC. $3,035.00 10/12/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998404229
Principal investigator 1 ABBVIE INC. $2,643.00 10/12/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998404231
Principal investigator 1 ABBVIE INC. $2,930.00 10/12/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998404233
Principal investigator 1 ABBVIE INC. $2,930.00 10/12/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998404235
Principal investigator 1 ABBVIE INC. $3,035.00 10/12/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998404239
Principal investigator 1 ABBVIE INC. $5,351.00 10/12/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998404241
Principal investigator 1 ABBVIE INC. $2,930.00 10/12/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998404243
Principal investigator 1 ABBVIE INC. $5,351.00 10/12/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998404245
Principal investigator 1 ABBVIE INC. $3,035.00 10/12/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998404247
Principal investigator 1 ABBVIE INC. $2,971.00 10/12/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 998404249
Principal investigator 1 ABBVIE INC. $1,092.73 07/11/2023 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CEN
A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer No dispute reported 06/30/2026 998390247